







Insulin resistance in PCOS

- Insulin resistance, polycystic ovaries and anovulation
- Insulin resistance, metabolic syndrome and diabetes
 in PCOS

Polycystic ovary syndrome

- Commonest cause of anovulatory infertility (>80% of cases) and of hirsutism
- Characterised by clinical (hirsutism/acne) and/or biochemical evidence of androgen excess
- Classic biochemical features are raised serum concentrations of LH and androgens
- Also associated with a characteristic metabolic disturbance and increased risk of type 2 diabetes (& GDM)
- Aetiology involves genetic and environmental factors

Insulin resistance in PCOS

- · Insulin resistance, polycystic ovaries and anovulation
- Insulin resistance, metabolic syndrome and diabetes
 in PCOS





















































- Oestradiol and progesterone concentrations higher in anovPCOS than in normal early follicular phase
- Results in suppression of FSH and arrest of follicle maturation (Chavez-Ross et al, J Maths Biol, 1997; Franks, Stark & Hardy, Hum Reprod Update, 2008)







Insulin resistance in the ovary?

- Anovulatory, hyperandrogenaemic women with PCOS are insulin resistant
- Hyperinsulinaemia implicated in mechanism of anovulation
- Does the polycystic ovary "read" the high circulating insulin levels?

























Insulin/LH effects in GL cells from anovulatory PCO: summary

- Insulin-stimulated glucose metabolism impaired (but LH action not affected)
- Insulin-stimulated steroidogenesis not significantly impaired (but LH-stimulated steroidogenesis amplified)



Insulin resistance in the polycystic ovary: summary

- Anovulation in PCOS is associated with insulin resistance and hyperinsulinaemia
- Hyperinsulinaemia contributes to the mechanism of follicle arrest and anovulation in PCOS
- Insulin resistance in the polycystic ovary differentially affects insulin-mediated glucose uptake and metabolism
- What is the defect in the insulin signalling pathway?

Insulin resistance in PCOS

- · Insulin resistance, polycystic ovaries and anovulation
- Insulin resistance, metabolic syndrome and diabetes
 in PCOS

Gestational diabetes in women with PCOS

- High prevalence (52%) of polycystic ovaries in women with history of GDM
 Kousta *et al*, *Clin Endocrinol* 2000 **53** 501-7
- Women with PCOS at increased risk of GDM
 (OR 2.94 (1.7 5.1))
 Boomsma et al, Hum Reprod Update 2006 12 673-683 (meta-analysis)



















Increased risk of T2D in older women with proven PCOS

- 319 cases of PCOS age 56.7 (38 98) with reference group of 1060 subjects
- Increased risk of diabetes after adjustment for BMI: OR 2.2 (0.9 - 5.2)
- Higher risk if obese subjects included: OR 2.8 (1.5 5.5)

Wild et al, Clin Endocrinol 2000 52 595-600

Increased risk of T2D in women with symptoms of "PCOS"

- Relative risk of T2D in women with history oligomenorrhoea/irregular cycle: 2.08 (1.62 - 2.66)
- Independent of obesity but RR increased further in obese subjects: 3.86 (2.33 - 6.38)

Nurses Health II: Solomon et al, JAMA 2001 286 2421-6

Screening for metabolic disorders in PCOS

Rotterdam consensus meeting

- No test of insulin resistance is needed to make diagnosis of PCOS or to select treatment
- Obese women with PCOS (and/or those with abdominal obesity) should have an OGTT (or fasting glucose) and lipid profile
- Utility of these tests in non-obese women with PCOS is not yet known

Hum Reprod 2004 19 41-7

Who is at risk of T2D?

PCOS (2-fold) PCOS + obesity (3-fold) PCOS + obesity + FH of diabetes PCOS + obesity + GDM PCOS + obesity + IGT

Diagnostic criteria for PCOS

NIH 1990

Rotterdam 2003 Oligo- and/or

- Chronic anovulation
- Clinical and/or biochemical signs of hyperandrogenism (with exclusion of other aetiologies, eg CAH) (both criteria needed)
- anovulationClinical and/or biochemical signs of
- hyperandrogenismPolycystic ovaries
 - (2 of 3 criteria needed)

Zawadzki & Dunaif 1992, in *Polycystic Ovary Syndrome*, Dunaif et al (eds), Boston: Blackwell Scientific pp 377-84 Rotterdam ESHRE/ASRM sponsored PCOS Consensus Workshop Group (*Hum Reprod* 2004 19 41-7)











Metformin in treatment of PCOS

- Not useful for treatment of infertility or menstrual disturbances
- Not very effective for treatment of hirsutism
- May have a place in management of women at high risk of developing diabetes



Role of thiazolidinediones (glitazones) in PCOS

- Improvement in insulin sensitivity, androgens and cyclicity
- Lipids not significantly altered and weight increased
- Concern about safety, particularly in women of reproductive age

Summary

- Insulin resistance and abnormal $\beta\mbox{-cell}$ function are features of PCOS
- Hyperinsulinaemia contributes to anovulation in PCOS
- Hyperinsumational contributes to anovulation in PCOS
 Women with PCOS are at increased risk of developing metabolic syndrome and T2D
 Diet and lifestyle changes are most important ways of improving fertility and in prevention of diabetes in women with PCOS